By: Stacy Mitchell & Zack Freed (Pro Market)
When New York State Assemblyman Richard Gottfried set out to regulate a group of powerful corporate players in his state’s health care system, he was prepared to battle yet another muscular industry lobby. As chair of the Assembly’s Health Committee and a long-time advocate of health care reform, Gottfried has had plenty of fights with big insurers and providers over the years. This time, his enemies were Pharmacy Benefit Managers, or PBMs. PBMs manage prescription drug benefits for health insurers and state Medicaid programs, and Gottfried was seeing them engage in a pattern of price gouging and self-dealing.
What caught Gottfried off guard was the opposition he faced from another quarter: the Federal Trade Commission, created to safeguard Americans from concentrated corporate power, had taken a stance against state legislation like his that sought to rein in the PBMs.
PBMs were established in the 1960s to control drug costs, but they have since morphed into one of the most highly concentrated and least accountable profit centers in the health care industry. Just three PBMs—CVS Health, Express Scripts, and OptumRx— control more than 76 percent of the market. All three operate their own mail order pharmacies and one, CVS, owns the nation’s largest drugstore chain.
PBMs have a documented history of steering patients to their own pharmacies by cutting reimbursements to independent pharmacies, essentially driving them out of business. At the same time, PBMs have been bilking public health plans, especially state Medicaid programs. In Ohio alone, two PBMs were found to have charged the state $224 million more than they reimbursed pharmacies in 2017. PBMs are not required by federal law to disclose rebates they receive from drug makers or the spread between what they’re paid by insurers to fill a prescription and how much they pay out to the pharmacy that does so…
Featured News
Google’s Bid to End EU Antitrust Case with AdX Sale Rejected by Publishers
Sep 18, 2024 by
CPI
Google Challenges £7 Billion UK Lawsuit, Seeks Case Dismissal Over Alleged Market Abuse
Sep 18, 2024 by
CPI
GameStop CEO Ryan Cohen Fined Nearly $1M for Antitrust Violation in Wells Fargo Deal
Sep 18, 2024 by
CPI
French Regulator Approves FDJ’s Kindred €2.45B Acquisition with Conditions
Sep 18, 2024 by
CPI
UK Competition Authority Targets Greenwashing with New Fashion Compliance Rules
Sep 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández